Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Spyre Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 77 | 1 | 86 | +10 |
| Shares | 40.6M | 56 | 39.9M | −661.2K (−1.6%) |
| Value | $322.5M | $0 | $189.4M | −$133.1M (−41.3%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Spyre Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ClariVest Asset Management LLC | 174,919 | $832.0K | 0.03% |
| Jacobs Levy Equity Management, Inc | 144,093 | $684.0K | 0.00% |
| Acadian Asset Management LLC | 130,835 | $620.0K | 0.00% |
| Two Sigma Investments, LP | 64,511 | $306.0K | 0.00% |
| Alps Advisors Inc | 57,080 | $271.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 55,945 | $266.0K | 0.00% |
| Two Sigma Advisers, LP | 38,200 | $181.0K | 0.00% |
| Aristides Capital LLC | 35,763 | $170.0K | 0.10% |
| BIT Capital GmbH | 25,000 | $118.8K | 0.01% |
| Engineers Gate Manager LP | 15,000 | $71.0K | 0.00% |
| Delphia (USA) Inc. | 12,944 | $61.0K | 0.06% |
| Nisa Investment Advisors, LLC | 13,192 | $57.0K | 0.00% |
| Pinnacle Wealth Planning Services, Inc. | 10,130 | $48.0K | 0.01% |
| Group One Trading, L.P. | 5,300 | $25.0K | 0.00% |
| Public Employees Retirement System of Ohio | 3,893 | $18.0K | 0.00% |
| Allspring Global Investments Holdings, LLC | 1,334 | $6.00K | 0.00% |
| Captrust Financial Advisors | 171 | $1.00K | 0.00% |
| Point72 Hong Kong Ltd | 153 | $1.00K | 0.00% |
| Toronto Dominion Bank | 5 | $0 | 0.00% |
Sold out (9)
Institutions that held Spyre Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| AlphaCentric Advisors LLC | 110,000 | $875.0K |
| MetLife Investment Management | 15,353 | $122.1K |
| HighVista Strategies LLC | 13,137 | $105.0K |
| Metropolitan Life Insurance Co | 11,616 | $92.3K |
| Gsa Capital Partners LLP | 11,242 | $89.0K |
| Susquehanna International Group, LLP | 11,192 | $89.0K |
| Personal Cfo Solutions, LLC | 10,888 | $87.0K |
| Lazard Asset Management LLC | 8,801 | $69.0K |
| Penserra Capital Management LLC | 1,120 | $8.00K |
Not filed for Q4 2021 yet (1)
Institutions that held Spyre Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Berman Capital Advisors, LLC | 56 | $0 |